Validated U87 Xenograft Model:
Subcutaneous And Orthotopic Xenograft Tumor Model

By Altogen Labs, 11200 Menchaca Road, Suite 203, Austin, TX 78748
Phone: (512) 433-6177 | Email: info@altogenlabs.com

Bridging the Translational Gap in Glioblastoma Xenograft Studies

Glioblastoma multiforme (GBM) remains one of the most aggressive and lethal forms of primary brain cancer, characterized by rapid proliferation, diffuse infiltration, angiogenesis, and resistance to conventional therapies. Despite significant advances in molecular profiling and targeted treatment development, clinical outcomes for GBM patients have shown minimal improvement over recent decades. Preclinical models, particularly xenografts, play a central role in advancing our understanding of GBM biology and evaluating novel therapeutics. Among these, cell line-derived xenografts (CDXs) and patient-derived xenografts (PDXs) are widely employed. CDX models, typically established by transplanting established tumor cell lines such as U87 into immunodeficient mice, offer experimental consistency and scalability but often lack the heterogeneity and invasive behavior observed in patient tumors. Conversely, PDX models, generated by direct implantation of patient tumor tissues, better preserve the histological and molecular complexity of GBM but are limited by their cost, engraftment variability, and logistical constraints. The U87 glioblastoma cell line remains one of the most frequently used models in neuro-oncology due to its robust tumorigenic potential and well-characterized genotype. However, its phenotypic divergence from primary GBM, particularly in subcutaneous CDX models, underscores the need for refined strategies that enhance its clinical relevance. This includes orthotopic implantation, genetic modification, and transcriptomic validation to bridge the gap between experimental convenience and biological fidelity.

U87 Cell Line

The U87 glioblastoma cell line, originally derived from a human glioblastoma, has become a foundational model for studying glioblastoma multiforme (GBM) due to its ease of culture, consistent tumorigenicity, and well-characterized genetic profile. U87 cells exhibit rapid proliferation, high GFAP expression, and robust tumor formation in immunodeficient mice, making them suitable for investigating glioma biology, therapeutic efficacy, and angiogenesis. However, despite their widespread use, U87 cells display significant limitations in faithfully modeling patient tumors. Notably, they lack key mutations frequently observed in primary GBM, such as EGFRvIII, and do not exhibit the infiltrative behavior characteristic of clinical gliomas when implanted subcutaneously. Transcriptomic analyses have further revealed substantial divergence from the gene expression profiles of primary GBM tissues, raising concerns about their translational relevance. Additionally, extensive passaging and the prevalence of a widely distributed variant of U87 (of likely Swedish origin) have contributed to biological drift and inconsistencies across studies. These limitations underscore the need for more physiologically representative models to better recapitulate the complex molecular and microenvironmental features of GBM.

Altogen Labs Validated U87 Xenograft Model

In xenotransplantation studies, human cancer cells are implanted into immunodeficient mice to evaluate disease progression and assess the efficacy of experimental therapies in a biologically relevant *in vivo* environment. This technique enables researchers to observe tumor dynamics, including growth kinetics, response to treatment, and mechanisms of resistance, within the context of a living host. The U87 cell line, originally derived from a human glioblastoma, is one of the most frequently used cell lines for generating cell line-derived xenograft (CDX) models. Altogen Labs offers a validated U87 xenograft model, supporting researchers with a reproducible and well-characterized system for preclinical glioblastoma investigations.



Figure 1. Growth kinetics of U87 glioblastoma xenografts in immunocompromised mice following subcutaneous transplantation, mean values +/- SEM (Altogen Labs).

© Altogen, Inc. 2025 Material may not be reproduced or distributed without written permission from Altogen Labs.

The U87 xenograft model retains a wild-type p53 genotype and has become foundational in the study of glioblastoma, particularly in investigations focused on tumor vascularization. This model has been extensively used to evaluate angiogenic signaling pathways and to test the efficacy of anti-angiogenic therapeutic agents. Although the model does not fully replicate the invasive phenotype or genetic heterogeneity of primary glioblastoma tumors, its historical relevance and robust tumorigenicity make it highly valuable for early-phase drug screening. Altogen Labs leverages this model to support the development of targeted therapeutics, offering *in vivo* study services that include tumor growth assessment, treatment response analysis, and histopathological evaluation.



Figure 2. Final tumor weight at study endpoint in immunocompromised mice with U87 glioblastoma xenografts. Mice were treated with cisplatin or received buffer only. Data presented as mean ± SEM. Treatment with cisplatin significantly reduced tumor burden compared to control (Altogen Labs).

U87 Subcutaneous Xenografts in Research

Subcutaneous xenograft transplantation using the U87 glioblastoma cell line is a widely employed preclinical model for studying tumor growth, therapeutic response, and resistance mechanisms in glioma research. Derived from a human astrocytoma, U87 cells readily form vascularized, well-demarcated tumors when injected subcutaneously into immunodeficient mice, enabling reproducible and accessible *in vivo* experimentation. This model has been instrumental in evaluating chemotherapeutics such as temozolomide and targeted agents including VEGF and EGFR inhibitors, particularly in the context of angiogenesis. Despite its experimental utility, the model lacks key features of clinical glioblastoma, including invasive growth and microenvironmental complexity, and concerns have been raised regarding genetic drift and divergence from the original tumor phenotype. These limitations necessitate cautious interpretation of results and often warrant complementary use of orthotopic or patient-derived models. Altogen Labs offers an in-house validated U87 subcutaneous xenograft model, supporting early-phase oncology studies with standardized protocols and comprehensive analytical endpoints.

Intracranial Glioblastoma Modeling Using U87 Cells

Orthotopic xenograft transplantation using the U87 glioblastoma cell line offers a biologically relevant model for studying tumor progression, therapeutic response, and intracranial drug delivery within the native brain environment. Stereotactic injection of U87 cells into the striatum or cortex of immunodeficient mice enables controlled tumor formation that reflects key aspects of glioblastoma localization, facilitating longitudinal analysis using imaging and histopathology. While U87-derived tumors in this setting lack the diffuse infiltration characteristic of primary glioblastomas, they are well-suited for assessing drug penetration across the blood-brain barrier and the efficacy of targeted treatments. Notable studies have shown that genetic manipulations, such as SNORD47 overexpression and HOTAIR knockdown, can significantly alter tumor behavior and survival outcomes in orthotopic models, while additional research has demonstrated the feasibility of advanced delivery methods like focused ultrasound-enhanced chemotherapy. Although the model has limitations related to invasiveness and tumor heterogeneity, it remains widely used in preclinical glioblastoma research due to its reproducibility and relevance for evaluating intracranial therapeutic strategies.

Case Study: U87 Glioma Cells Drive Tau Aggregation via Soluble CD44 Secretion

In a study published in *Experimental & Molecular Medicine* journal, Lim *et al*. investigated a mechanistic link between glioblastoma pathology and neurodegeneration, using the U87 cell line to establish a xenograft model and secretome system. The central finding of the study is that soluble CD44 (sCD44), secreted by U87 cells, induces tau hyperphosphorylation and aggregation, which in turn promotes neuronal degeneration. U87-conditioned media significantly increased tau aggregation in tau-BiFC reporter cells, elevated phospho-tau levels at Ser199 and Ser396, and shortened neurite outgrowth in primary rat hippocampal neurons. Secretome profiling through FPLC and mass spectrometry identified sCD44, SPARC, and LDHA as candidate proteins, but only siRNA-mediated knockdown of CD44 in U87 cells abolished tau-inducing activity. Direct injection of purified sCD44 into the hippocampus of tau transgenic mice further validated its neurodegenerative effect, as shown by increased AT8-positive neurons and elevated tau pathology in brain regions distal to the tumor. Notably, U87-derived sCD44 was found to be spatially correlated with sites of tau aggregation in the xenografted brains.

© Altogen, Inc. 2025 Material may not be reproduced or distributed without written permission from Altogen Labs.

The data reveal a consistent pattern in which U87 cells, through high CD44 expression and secretion of sCD44, drive tau pathology both *in vitro* and *in vivo*. The correlation between regions of sCD44 accumulation and tau aggregation strongly supports the paper's hypothesis that glioblastoma-secreted factors can propagate neurodegenerative changes. Methodologically, the study benefits from the use of multiple glioblastoma lines (including U87, T98G, HS683), appropriate controls, and both *in vitro* and *in vivo* models, thereby enhancing the robustness of the findings. However, the reliance on a single glioblastoma xenograft model (U87) limits generalizability, given U87's well-documented lack of infiltrative behavior and limited resemblance to primary GBM heterogeneity. Furthermore, while the use of tau-BiFC sensor cells provides a sensitive readout for aggregation, it may not fully capture the complexity of tau pathology *in vivo*. Nonetheless, the implications are substantial: the identification of sCD44 as a glioblastoma-derived mediator of tauopathy opens new avenues for understanding the intersection between brain tumors and neurodegeneration. Future studies should assess whether sCD44 plays similar roles in patient-derived xenografts or infiltrative glioma models and whether blocking CD44 cleavage can mitigate glioma-induced neuronal damage.

Additional Case Study: Targeting PI3K/Akt/mTOR via mGluR1 Blockade in U87 Cells

A study published in *Cellular Physiology and Biochemistry* journal by Zhang *et al*. examined the therapeutic potential of targeting metabotropic glutamate receptor 1 (mGluR1) in glioblastoma using the U87 cell line. The study utilized siRNA knockdown and selective pharmacological inhibitors, Riluzole and BAY36-7620, to suppress mGluR1 function and assess effects on U87 cell behavior. Inhibition of mGluR1 significantly reduced cell viability, increased LDH release, and induced apoptosis via caspase-3 and PARP activation. Cell cycle analysis revealed G0/G1 arrest with corresponding downregulation of cyclin D1 and CDK4. mGluR1 suppression also markedly decreased cellular invasion and migration, effects that were reversed by the mGluR1 agonist L-quisqualic acid. Mechanistically, these anti-proliferative and anti-migratory effects were linked to reduced phosphorylation of PI3K, Akt, mTOR, and p70S6K, indicating downregulation of the PI3K/Akt/mTOR pathway. *In vivo* validation using a subcutaneous U87 xenograft model in athymic nude mice confirmed that both pharmacologic and genetic mGluR1 inhibition led to significant tumor growth suppression without systemic toxicity. While the study design was comprehensive and included multiple orthogonal assays, its reliance on a single glioma model and use of ectopic rather than orthotopic implantation limit its translational scope. Nonetheless, the results provide strong evidence that mGluR1 contributes to glioma pathogenesis in U87 cells and identify it as a promising therapeutic target. The findings warrant further validation in invasive glioma models and patient-derived systems to fully explore clinical applicability.



Figure 3. Tumor growth kinetics following subcutaneous implantation of human tumor cells in immunodeficient mice. Animals were treated with either vehicle control or a reference compound (10 mg/kg), and tumor volume was measured at regular intervals. Treatment with the reference compound significantly delayed tumor progression compared to control, mean values +/- SEM.

Enhanced Antitumor Activity in U87 Cells via Dual-Drug Nanotherapy

Paclitaxel (PTX) and temozolomide (TMZ) are two chemotherapeutic agents with distinct mechanisms of action that can produce a synergistic antitumor effect when administered together, particularly in glioblastoma treatment. Using the U87 glioblastoma cell line, studies have demonstrated that co-encapsulation of PTX and TMZ into mPEG-PLGA nanoparticles enhances therapeutic efficacy through sustained drug release, improved cellular uptake, and reduced systemic toxicity. *In vitro* assays reveal that a 1:5 PTX to TMZ ratio yields the strongest synergy in U87 cells, with significantly lower IC50 values and combination drug index (CDI) scores below 1. This enhanced cytotoxicity is accompanied by increased apoptosis, as shown by flow cytometry and MTT viability assays. Nanoparticle formulations maintain drug concentrations over extended periods, which supports prolonged exposure and higher apoptotic response. *In vivo*, these nanoparticles reduce tumor burden more effectively than free drug mixtures, and they do so without causing significant weight loss, suggesting reduced off-target toxicity. The experimental design employed well-characterized polymeric carriers, consistent dosing schedules, and statistically validated outcomes.

© Altogen, Inc. 2025 Material may not be reproduced or distributed without written permission from Altogen Labs.

Overcoming TMZ Resistance in U87 Xenografts with SN-38 Delivery

Temozolomide (TMZ) is a first-line chemotherapeutic agent for glioblastoma, but its effectiveness is often limited by acquired resistance. In contrast, SN-38, the active metabolite of irinotecan, exerts antitumor effects through topoisomerase I inhibition, offering a mechanistically distinct approach. In glioblastoma models utilizing U87 and TMZ-resistant U87-TR cells, combining SN-38 with TMZ significantly improves therapeutic outcomes. When SN-38 is delivered via biodegradable polymeric microparticles for sustained intracranial release, it induces potent cytotoxic effects in U87 cells with nanomolar-range IC50 values that decrease over time. In both TMZ-sensitive and TMZ-resistant U87-derived intracranial xenografts, combination therapy markedly reduces tumor growth, suppresses cellular proliferation, and enhances apoptosis. Bioluminescence imaging and survival analysis consistently show superior outcomes compared to standard treatments. Histopathological assessments reveal reduced central necrosis and increased GFAP expression, indicating diminished malignancy and possible re-differentiation of glioma cells. Notably, this regimen also prevents spinal metastases in aggressive U87-TR models, suggesting improved control of tumor dissemination. These results support the rationale for combining mechanistically distinct agents using localized delivery systems to overcome resistance and enhance efficacy in glioblastoma, with U87 models serving as a valuable platform for preclinical evaluation.

RND1 Suppresses U87 Tumor Progression via AKT Signaling

The U87 glioblastoma cell line, widely used in preclinical studies, plays a central role in elucidating molecular mechanisms underlying tumor progression and chemoresistance. In this context, the RND1 gene has emerged as a key regulator of epithelial-mesenchymal transition (EMT) and temozolomide (TMZ) sensitivity. Overexpression of RND1 in U87 cells led to significant reductions in cell proliferation, migration, and colony formation. These phenotypic changes were accompanied by increased expression of anti-EMT markers such as E-cadherin and decreased levels of pro-EMT proteins including N-cadherin, vimentin, Snail1, and MMP2. Knockdown of RND1 reversed these effects, enhancing tumor-like behaviors and promoting EMT. At the signaling level, RND1 suppressed phosphorylation of AKT and its downstream effector GSK3β, identifying the AKT/GSK3β axis as a critical mediator of its tumor-suppressive function. Notably, U87 cells rendered resistant to TMZ (U87-TR) exhibited heightened AKT signaling and mesenchymal features, both of which were mitigated by RND1 overexpression. Pharmacological activation of AKT abrogated these effects, confirming the pathway's involvement. *In vivo*, RND1 overexpression suppressed tumor growth and improved TMZ responsiveness in xenograft models. These findings support a model in which RND1 inhibits oncogenic behavior in U87 cells by modulating EMT through AKT signaling and sensitizing cells to TMZ, underscoring its relevance as a potential therapeutic target in glioblastoma.

The U87 cell line, derived from a human malignant glioblastoma, serves as one of the most extensively studied and utilized models in neuro-oncology research. These cells exhibit key molecular and phenotypic traits characteristic of glioblastoma multiforme, including rapid proliferation, a high degree of tumorigenicity, and the capacity for local tissue invasion. Genetically, U87 cells harbor notable alterations such as mutations in the tumor suppressor gene p53 and amplification or overexpression of the epidermal growth factor receptor (EGFR), both of which are frequently observed in primary glioblastoma tumors. These oncogenic features contribute to dysregulated cell signaling, enhanced survival, and resistance to standard therapies. U87 cells are therefore widely employed in studies investigating gliomagenesis, therapeutic resistance mechanisms, and the evaluation of chemotherapeutic and targeted agents.



Figure 4. *In vivo* xenograft services for the U87 MG glioblastoma model at Altogen Labs, including tumor growth studies, drug efficacy testing, metastatic models, and imaging-based analyses.

© Altogen, Inc. 2025 Material may not be reproduced or distributed without written permission from Altogen Labs.

In vivo, U87 xenograft models provide a highly adaptable platform for studying tumor growth kinetics, treatment efficacy, and systemic toxicity under well-controlled experimental conditions. A wide range of preclinical endpoints can be measured, including tumor growth delay (TGD), tumor growth inhibition (TGI), and survival analysis. The model supports various administration routes such as intravenous, intraperitoneal, intratumoral, intranasal, subcutaneous, and oral gavage, as well as orthotopic transplantation that better replicates the native brain microenvironment. Advanced drug delivery methods including continuous infusion, pump-controlled intravenous injection, and microinjection techniques enhance the precision of therapeutic delivery. Additional study parameters such as immunohistochemical staining, blood chemistry analysis, gross necropsy, and histopathological assessment provide detailed insight into tumor biology and systemic treatment effects. Positive control groups using agents like cisplatin, doxorubicin, or cyclophosphamide establish reference points for evaluating novel therapies. Furthermore, non-invasive imaging techniques, including fluorescence-based whole-body imaging, allow for longitudinal monitoring of tumor progression and treatment response, thereby increasing the translational value of the U87 xenograft model in glioblastoma research.



Figure 5. Summary of *in vivo* toxicology services offered by Altogen Labs, including acute, sub-chronic, and chronic toxicity studies in rodent models using multiple routes of administration. All studies comply with GLP and GMP standards and can be customized for specific compound evaluations.

References:

Lim S, Kim D, Ju S, Shin S, Cho IJ, Park SH, Grailhe R, Lee C, Kim YK. Glioblastoma-secreted soluble CD44 activates tau pathology in the brain. *Exp Mol Med.* 2018 Apr 6;50(4):1-11. doi: 10.1038/s12276-017-0008-7. PMID: 29622771; PMCID: PMC5938049.

Sun Q, Xu J, Yuan F, Liu Y, Chen Q, Guo L, Dong H, Liu B. RND1 inhibits epithelial-mesenchymal transition and temozolomide resistance of glioblastoma via AKT/GSK3-β pathway. *Cancer Biol Ther.* 2024 Dec 31;25(1):2321770. doi: 10.1080/15384047.2024.2321770. Epub 2024 Mar 5. PMID: 38444223; PMCID: PMC10936657.

Xu Y, Shen M, Li Y, Sun Y, Teng Y, Wang Y, Duan Y. The synergic antitumor effects of paclitaxel and temozolomide co-loaded in mPEG-PLGA nanoparticles on glioblastoma cells. *Oncotarget*. 2016 Apr 12;7(15):20890-901. doi: 10.18632/oncotarget.7896. PMID: 26956046; PMCID: PMC4991499.

Yang TC, Liu SJ, Lo WL, Chen SM, Tang YL, Tseng YY. Enhanced Anti-Tumor Activity in Mice with Temozolomide-Resistant Human Glioblastoma Cell Line-Derived Xenograft Using SN-38-Incorporated Polymeric Microparticle. *Int J Mol Sci*. 2021 May 24;22(11):5557. doi: 10.3390/ijms22115557. PMID: 34074038; PMCID: PMC8197307.

Zhang C, Yuan XR, Li HY, Zhao ZJ, Liao YW, Wang XY, Su J, Sang SS, Liu Q. Anti-cancer effect of metabotropic glutamate receptor 1 inhibition in human glioma U87 cells: involvement of PI3K/Akt/mTOR pathway. *Cell Physiol Biochem*. 2015;35(2):419-32. doi: 10.1159/000369707. Epub 2015 Jan 15. PMID: 25613036.

Keywords: U87, xenograft, *in vivo*, cancer, preclinical, research, brain, *in vivo* pharmacology, brain cancer, glioblastoma, orthotopic, CDX, PDX

© Altogen, Inc. 2025 Material may not be reproduced or distributed without written permission from Altogen Labs.